From the Department of Medicine, University of Leeds (RECEIVED FOR PUBLICATION JUNE 16, 1954) Very little is known about the aetiology of acute attacks of gout or the mode of action of colchicine in relieving them. Their relationship to high serum uric acid levels and urate deposition is obscure, for maintaining serum levels at normal together with a negative urate balance does not prevent their occurrence. Fortunately the vast majority of acute attacks readily respond to colchicine in proper dosage, and the few exceptions may be treated with phenylbutazone ("Butazolidin").
Unlike the acute variety, chronic gout appears to be closely related to high serum and tissue fluid uric acid levels with supersaturation and deposition of urates in various tissues, especially joint structures and bursae. Uric acid deposition induces a chronic inflammatory reaction, and increasing size of the deposits leads to progressive and even total destruction of the affected joints. Urate deposition is often confirmed by the presence of tophi, but even in their absence it may be inferred by isotopic uric acid dilution studies. Such studies have shown that the miscible pool of uric acid in normal adults ranges from 731 to 1,341 mg. (Benedict, Forsham, and Stetten, 1949; Geren, Bendich, Bodansky, and Brown, 1950; Bishop, Garner, and Talbott, 1951) . In gouty persons the miscible pool is greatly increased and may be as high as 30,000 mg. (Benedict and others, 1950) . This enormous increase cannot be accounted for by uric acid in solution and must indicate the presence of solid phase urate which has taken part in dilution of the isotope.
The patient with chronic gout complains of increasing stiffness, pain, and deformity of one or more joints, symptoms which are unaffected by colchicine and which ultimately give rise to severe crippling and invalidism. Until 1950, it had not been found possible to maintain the serum uric acid at normal levels, and the progress of chronic gouty changes had never been arrested. Since 1950, * This paper is based on a communication to the Heberden Society on May 7, 1954. however, the continuous administration of sodium salicylate or probenecid ("Benemid") has been shown to maintain a prolonged lowering in the serum uric acid levels, and this has proved of great value in the treatment of chronic gout.
The effect of sodium salicylate in increasing urinary uric acid excretion in gouty persons has been known since 1877, and its ability to reduce the serum uric acid since 1914. When given continually it is a most useful drug in maintaining the serum uric acid of chronic gouty persons at a normal or near normal level, an effect which persists for upwards of 3 years and is accompanied by complete or very marked improvement in the symptoms and signs of the disorder (Marson, 1952 (Marson, , 1953a . The lowering of serum uric acid levels is accompanied by mobilization of deposited urate, as shown by shrinkage or total disappearance of tophi, recalcification of areas of bone absorption, and a prolonged increase in the urinary uric acid levels (Marson, 1952 (Marson, , 1953a . Isotopic studies have shown a marked diminution in the metabolic pool of uric acid during salicylate therapy (Benedict and others, 1950) . The delayed recognition of the beneficial effects of sodium salicylate may have been due to the following reasons:
(1) Gutman (1950) and Talbott (1953a) rejected continuous administration of salicylate because the early development of toxic symptoms prevents adequate dosage. It has been shown, however, that, although most patients suffer salicylism initially, a majority develop a tolerance within 1-6 weeks, and thereafter are able to take the required dosage with no more than occasional and minor symptoms (Marson, 1953a) .
(2) Bauer and Klemperer (1944) reported that the effect of salicylate on depressing the serum uric acid is short-lived. This assertion has since been disproved and patients have maintained marked lowering of serum uric acid for periods of upwards of 3 years.
(3) Jennings (1937) reported that normal levels of blood uric acid could be maintained by administering sodium salicylate in a daily dosage of 80 gr. 3 or 4 days ANNALS OF THE RHEUMATIC DISEASES a week. Bauer and Klemperer (1944) and Marson (1953a) were unable to confirm this finding. Such intermittent therapy has never been shown to arrest chronic gouty changes.
Wolfson and others (1948) reported that caronamide (4'-carboxyphenyl-methanesulphonanilide) increased uric acid excretion in normal subjects, and Gutman (1950) reported the use of this drug in thirteen gouty subjects. With a daily dosage of 12 to 13 5 g. a marked lowering in the serum uric acid levels resulted. However, the large number of tablets consumed daily was objectionable, and various toxic reactions occurred, including gastrointestinal symptoms, drug fever, and drug rash. This drug is no longer used.
A new benzoic acid derivative, probenecid ("Benemid": p-(di-n-propylsulfamyl)-benzoic acid), structurally related to caronamide, introduced into clinical medicine by Boger and others (1950) , was found to have a marked effect on blocking the tubular secretion of penicillin, para-aminosalicylic acid, para-aminohippuric acid, and phenolsulphonphthalein. It was later shown to block tubular reabsorption of certain glomerular constituents (Schneider and Corcoran, 1950) including uric acid (Gutman, 1950) . These effects were similar to those obtained with caronamide but could be obtained with a much smaller dosage, 2 g. probenecid being equivalent to 24 g. caronamide. Since that time various reports have been published on the value of probenecid in the treatment of chronic gout, and there can be no doubt that, in a daily dosage of 2 g., it causes a marked lowering in serum uric acid levels, a marked initial increase in urinary uric acid excretion, and great general improvement in chronic gouty patients. It also causes a shrinkage in the metabolic pool of uric acid (Bishop, Rand, and Talbott, 1951) . Gutman (1950 Gutman ( , 1951 reported a series of fourteen patients in whom probenecid in a daily dosage of 2 g. caused a mean increase in urinary uric acid excretion of 58*5 per cent., and a sustained fall in serum uric acid to approximately half the initial level. In a series of fifteen patients a dose of 1 g. daily produced a mean decrease of 24 per cent. in serum level (Gutman, 1951b) . Pascale and others (1952) reported that in seventeen gouty subjects 2 g. probenecid daily induced a fall in the serum uric acid level at the end of 72 hrs to 42-70 per cent. of previous levels with an average fall to 55 per cent. Impaired renal function was demonstrated in three further subjects in whom probenecid failed to lower the serum uric acid. Two illustrations (Talbott, 1953b) It has been reported that when salicylates are given concomitantly with probenecid the uricosuric effect is nullified (Gutman and Yu, 1952) . Pascale and others (1952) found that, whereas 2 g. probenecid daily effected a marked lowering in the serum uric acid level in gouty patients, the addition of 1 -3 g. acetylsalicylic acid 6-hrly nullified this effect.
It would appear likely that the beneficial effects of both probenecid and salicylates are dependent upon the lowering of serum (and tissue fluid) uric acid levels, with arrest of further deposition of urate and partial reabsorption of deposits. If this hypothesis is correct it becomes important to assess the relative merits of salicylate and probenecid in lowering the serum uric acid level, and an attempt to do this is recorded below.
Patients Investigated and Methods A series of 21 chronic gouty patients has been studied closely over the past 45 months, and an attempt has been made to maintain a continuous lowering in the serum uric acid levels with either salicylates or probenecid therapy.
The diagnosis of gout was based upon a history of attacks of acute arthritis, the witnessing of one or more such attacks together with response to colchicine therapy (O -5 mg. 2-hrly until pain disappears or diarrhoea occurs), and a raised serum uric acid level. Approximately half the patients had demonstrable tophi and a further half had a family history of gout. The patient was judged to be suffering from chronic gout if the joint pain had persisted for longer than 3 months and was unaffected by a course of colchicine therapy.
All patients had a minimum of three estimations of the uric acid before therapy and were advised to take a normal diet and an increased fluid intake. They were all supplied with crystalline colchicine tablets (O 5 mg.) with instructions to treat all acute episodes with one tablet 2-hrly until the pain has disappeared or diarrhoea occurred. They then commenced salicylate or probenecid therapy and were usually admitted to hospital for close study at this time. After discharge they attended, a gout clinic at intervals of not longer than a month, and at each visit progress was recorded, uric acid estimated, and the appropriate therapy prescribed. Some patients received salicylate continuously and others probenecid . Four (Cases 8, 15, 19, 11) (two subjects only). All test days were separated by at least 3 clear days. The 2-hr urine samples were tested for uric acid (Bidmead, 1951) , and creatinine (Folin, 1914) ; Fig. 7 shows mean results expressed as uric acid : creatinine ratios. It was assumed that neither drug has any significant effect upon creatinine excretion. A similar technique has been used in assessing the relative uricosuric effects of ACTH and sodium salicylate (Marson, 1953b) .
Estimations of serum salicylate were done in six subjects (Cases A-F) in similar circumstances to the patients on test day (b). The serum salicylate was estimated by the method of Smith and Talbott (1950) .
In another individual (Case X), not one of the series of 21, a further investigation was carried out to assess the results of combining probenecid administration with salicylate. The subject was male, aged 42 years, and suffered from chronic gout. He was in hospital and received a normal mixed diet with the exclusion of high purine foods. The serum and total urinary uric acid were estimated daily and, after an initial control period, sodium salicylate was administered in a dosage of 30 gr. 8-hrly. This was continued, and after 8 days, probenecid was also administered in a dosage of 0 5 g. 6-hrly and the tests continued for a further 8 days (Fig. 8 ).
Results
Seventeen chronic gouty patients received continuous salicylate therapy for periods of 9-45 months. During this time the serum uric acid was estimated at least once every 4 weeks. Table I shows the only four of the seventeen patients was it found impossible to maintain the level below the mean for normal persons. The four exceptions comprised the three patients in whom salicylism was troublesome and the fourth patient was the most jovial but probably least reliable of the series. Table II illustrates similar figures for six chronic gouty patients (Cases 11, 15, (18) (19) (20) (21) to whom probenecid was administered continuously for periods of 12-19 months. In no patient was it found possible to maintain the serum uric acid at a mean level below 50 per cent. of initial figure. In only one case was the uric acid reduced to a level below the mean for normal persons. It should be noted that the initial uric acid levels of patients in Table It was somewhat higher than that of those in Table I (mean 8 35 and 7-5 mg./I00 ml. respectively).
During both salicylate and probenecid therapy, the serum uric acid was maintained at an average of 50-2 and 67 9 per cent. of the initial levels respectively (observed difference = 2 64 x standard error).
Four patients (Cases 8, 11, 15, 19) Probenecid, like salicylate, causes an early maximal depression of serum uric acid which is not maintained (Fig. 4, Case 18) . The lowest level (3 9 mg./100 ml.) occurred on the seventh day, and the level then rose gradually during the next 3 months. The mean level during 19 months of treatment was 5'8 mg./100 ml.
Figs 5 and 6 illustrate graphically the relative effects of sodium salicylate and probenecid in lowering the serum uric acid level. In Fig. 5 (Case 15) every estimation of uric acid during salicylate therapy is seen to be lower than the lowest reading during probenecid administration. In Fig. 6 (Case 8) only two of the many uric acid estimations during sodium salicylate therapy were higher than the three estimations made during probenecid therapy. Six patients suffered gastrointestinal symptoms:
(1) Case P. Female, aged 49 years, anorexia, nausea, and vomiting developed on the second day of treatment. The symptoms persisted for a week and disappeared within 36 hrs of stopping further therapy.
(2) Case Q. Male, aged 45 years, epigastric discomfort and flatulence occurred from the second to fourteenth day, after which he became symptom-free. He was normally singularly free from alimentary symptoms and firm persuasion was necessary to get him to continue taking the drug.
(3) Case 8. Male, aged 51 years, anorexia and nausea occurred on the second day and vomiting on the third. Probenecid was stopped and no further symptoms occurred on recommencing the drug 2 months later.
(4) Case R. Male, aged 51 years, heartburn and a cramp-like pain across the upper abdomen occurred on the fourteenth day. The symptoms were fairly severe for a few days but gradually disappeared during the next 3 weeks.
(5) Case S. Male, aged 44 years, anorexia and nausea occurred from the third to seventh day of therapy. n tration of between 2-6 mg./100 ml. (Boger and others, 1950) . Previous reports have stated that the coincident administration of probenecid and salicylates nullifies the uricosuric effect (Pascale and others, 1952; Gutman and Yu, 1952 Allergic reactions to probenecid occurred in two of forty cases treated by Gutman and Yu (1952) . Two of the present series of fifteen patients suffered severe sensitivity reactions to probenecid. Six patients suffered gastro-intestinal symptoms at the onset of treatment, but these disappeared with continued therapy.
The toxic effects of continuous salicylate therapy have been discussed previously (Marson, 1953a) ; further experience has amplified the earlier finding that, after the first few weeks, the large majority of patients tolerate the required dosage of salicylate (usually 90 gr. daily) with either complete freedom from salicylism or occasional and mild tinnitus and deafness. At the start of treatment it is useful to have the patients in hospital so that the salicylate dosage can be regulated to minimize the early toxic symptoms. In only five of forty patients have toxic symptoms been sufficiently severe to prevent continuous therapy in a dosage sufficient to maintain an appreciable lowering of the serum uric acid levels.
One difficulty with sodium salicylate therapy is the unpleasant taste of this drug in liquid form, but this can be avoided by dispensing it in capsules. Another disadvantage is the development of increased deafness in those already partially deaf; in such cases probenecid is to be preferred.
It is important to stress that, with the exception of those patients with impaired renal function, continued administration of salicylate or probenecid will effect a cure in most cases of chronic gout. (6) L'effet uricosurique d'une dose de 6,5 grammes de salicylate de soude fut deux fois plus grand que celui d'une dose de 2 grammes de probenecid, pendant six heures apres administration de chaque medicament.
Summary
(7) L'administration simultanee de probenecid et de salicylates n'annulait pas l'effet uricosurique.
(8) Des sympt6mes toxiques se sont presents chez neuf sur quinze malades au probenecid. Generalement une tolerance apparaissait vite mais on s'est heurte a deux reactions graves demandant la suppression du medicament.
Salicilato de sodio y probenecid (Benemid) en el tratamiento de la gota cr6nica-valoraci6n de sus efectos relatives sobre la baja de la cifra skrica de acido SUMARIO (1) Se ha tratado de comparar la accion reductive del salicilato de sodio y del probenecid sobre el acido uirico sanguineo de los gotosos.
(2) La mayor caida de la cifra de acido urico sanguineo ocurri6 pocos dias despues de empezar el tratamiento con el salicilato o el probenecid. Esta caida, susceptible de crear una opinion exagerada respecto a los efectos de estos medicamentos, no se mantuvo con prolongar el tratamiento.
(3) Diecisiete gotosos cr6nicos fueron tratados sin interrupci6n con salicilatos durante 9 a 54 meses. La cifra media de acido urico sangufneo fue el 50 por ciento de la cifra inicial y en 13 de los 17 enfermos no alcanz6 la media para sujetos normales.
(4) Seis gotosos cr6nicos fueron tratados con probenecid durante 12 a 19 meses. La cifra media de acido urico sanguineo fue el 68 por ciento de la cifra inicial y en uno de ellos no alcanz6 la media normal.
(5) Cuatro enfermos recibieron el salicilato y el probenecid durante varios periodos. En todos los casos el efecto reductive del salicilato sobre la tasa serica del Acido urico fue ma's pronunciado.
(6) Durante las seis horas despues de su administracion, el efecto uricosurico de una dosis de 6,5 gramos de salicilato de sodio fue dos veces mayor que 6l de una dosis de 2 gramos de probenecid.
(7) La administraci6n simultanea de probenecid y de salicilato no anulaba el efecto uricosurico. (8) Sintomas t6xicos presentaronse en nueve do los quince enfermos tratados con probenecid. Por lo general, una tolerancia solia establecerse rapidamente pero en dos casos hubo una reacci6n grave necesitando la cesaci6n del medicamento.
